Ernexa Therapeutics Inc. has successfully completed its second closing of a private placement, raising approximately $6.0 million in gross proceeds. The company issued an aggregate of 47,717,087 shares of common stock and 9,332,000 pre-funded warrants. This follows an initial closing where Ernexa sold 9,934,016 shares of common stock and 509,736 pre-funded warrants. In total, the private placement has resulted in gross proceeds of around $7.0 million, bolstering the company's stockholders' equity to over $2.5 million. This move is part of Ernexa's strategy to comply with Nasdaq's continued listing requirements. The net proceeds from the issuance are intended for general working capital purposes.